ABSTRACT
This study unveiled the cadmium phytoremediation potential and its augmentation using 6-Benzylaminopurine in Strobilanthes alternata. Cadmium stress was provided by applying 250 mg/kg cadmium chloride in soil and 25 ppm of 6-BAP (25 ml) was administered to the plants as foliar spray. The results revealed high bioconcentration factor (BCF) (18.82 ± 0.54) and low translocation factor (TF) values (0.055 ± 0.002) for the plant based on which we strongly recommend S. alternata as a promising candidate for Cd phytoremediation. The phytostabilization potential of the plant was further enhanced by applying 6-BAP, which augmented its BCF to 22.09 ± 0.64 and reduced the TF to 0.038 ± 0.001. Cd toxicity caused a reduction of plant growth parameters, root volume, adaxial-abaxial stomatal indices, relative water content, tolerance index, moisture content, membrane stability index, and xylem vessel diameter in S. alternata. However, Cd + 6-BAP treated plants exhibited an increase of the same compared to Cd-treated plants. FTIR analysis of Cd + 6-BAP treated plants revealed increased deposition of hemicellulose, causing enhanced retention of Cd in the root xylem walls, which is largely responsible for increased phytostabilization of Cd. Therefore, 6-BAP application in S. alternata can be exploited to restore Cd-contaminated areas effectively.
The research paper "6-Benzylaminopurine Mediated Augmentation of Cadmium Phytostabilization Potential in Strobilanthes alternata" has established the Cd phytostabilization potential of the plant Strobilanthes alternata and also identified the role of 6-BAP in augmenting the Cd phytoremediation potential of this plant for the very first time. The physiological and anatomical changes in relation to the applied stress signals were also studied for the first time in S. alternata.
ABSTRACT
This study illustrates the salinity tolerance mechanisms in Volkameria inermis (a mangrove-associate), making it an ideal candidate for establishment in saline lands. The plant was exposed to 100, 200, 300, and 400 mM NaCl and the TI value indicates that the stress-imparting concentration was 400 mM. There was a decrease in biomass and tissue water, and a gradual increase in osmolytes like soluble sugars, proline, and free amino acids content was observed in plantlets with the increase in NaCl concentrations. Higher number of lignified cells in the vascular region of the plantlet's leaves treated with NaCl (400 mM) may influence the transport through the conducting tissues. SEM data reveals the presence of thick-walled xylem elements, an increased number of trichomes, and partially/fully closed stomata in the 400 mM NaCl-treated samples of V. inermis. In general, macro and micronutrient distribution tend to be affected in the NaCl-treated plantlets. However, Na content increased remarkably in plantlets treated with NaCl, and the highest accumulation was observed in roots (5.58-fold). Volkameria inermis can be a good option for phytodesalination in salt-affected areas since it is equipped with strong NaCl tolerance strategies and can be exploited for desalinization purpose of salt affected lands.
The phytodesalination potential of V. inermis was proved with the aid of physiochemical and anatomical studies, which was not yet revealed. The present study elucidated the level of NaCl tolerance in V. inermis and the development of associated adaptive responses.
Subject(s)
Plant Leaves , Sodium Chloride , Sodium Chloride/chemistry , Sodium Chloride/metabolism , Biodegradation, Environmental , Plant Leaves/metabolism , SalinityABSTRACT
Metabolomic investigations offers a significant foundation for improved comprehension of the adaptability of plants to reconfigure the key metabolic pathways and their response to changing climatic conditions. Their application to ecophysiology and ecotoxicology help to assess potential risks caused by the contaminants, their modes of action and the elucidation of metabolic pathways associated with stress responses. Heavy metal stress is one of the most significant environmental hazards affecting the physiological and biochemical processes in plants. Metabolomic tools have been widely utilised in the massive characterisation of the molecular structure of plants at various stages for understanding the diverse aspects of the cellular functioning underlying heavy metal stress-responsive mechanisms. This review emphasises on the recent progressions in metabolomics in plants subjected to heavy metal stresses. Also, it discusses the possibility of facilitating effective management strategies concerning metabolites for mitigating the negative impacts of heavy metal contaminants on the growth and productivity of plants.
Subject(s)
Metals, Heavy , Metals, Heavy/toxicity , Metals, Heavy/metabolism , Plants/metabolism , MetabolomicsABSTRACT
Photosynthesis, as one of the most important chemical reactions, has powered our planet for over four billion years on a massive scale. This review summarizes and highlights the major contributions of Govindjee from fundamentals to applications in photosynthesis. His research included primary photochemistry measurements, in the picosecond time scale, in both Photosystem I and II and electron transport leading to NADP reduction, using two light reactions. He was the first to suggest the existence of P680, the reaction center of PSII, and to prove that it was not an artefact of Chlorophyll a fluorescence. For most photobiologists, Govindjee is best known for successfully exploiting Chlorophyll a fluorescence to understand the various steps in photosynthesis as well as to predict plant productivity. His contribution in resolving the controversy on minimum number of quanta in favor of 8-12 vs 3-4, needed for the evolution of one molecule of oxygen, is a milestone in the area of photosynthesis research. Furthermore, together with Don DeVault, he is the first to provide the correct theory of thermoluminescence in photosynthetic systems. His research productivity is very high: ~ 600 published articles and total citations above 27,000 with an h-index of 82. He is a recipient of numerous awards and honors including a 2022: Lifetime Achievement Award of the International Society of Photosynthesis Research. We hope that the retrospective of Govindjee described in this work will inspire and stimulate the readers to continue probing the photosynthetic apparatuses with new discoveries and breakthroughs.
ABSTRACT
Microbes evolve rapidly by modifying their genomes through mutations or through the horizontal acquisition of mobile genetic elements (MGEs) linked with fitness traits such as antimicrobial resistance (AMR), virulence, and metabolic functions. We conducted a multicentric study in India and collected different clinical samples for decoding the genome sequences of bacterial pathogens associated with sepsis, urinary tract infections, and respiratory infections to understand the functional potency associated with AMR and its dynamics. Genomic analysis identified several acquired AMR genes (ARGs) that have a pathogen-specific signature. We observed that blaCTX-M-15, blaCMY-42, blaNDM-5, and aadA(2) were prevalent in Escherichia coli, and blaTEM-1B, blaOXA-232, blaNDM-1, rmtB, and rmtC were dominant in Klebsiella pneumoniae. In contrast, Pseudomonas aeruginosa and Acinetobacter baumannii harbored blaVEB, blaVIM-2, aph(3'), strA/B, blaOXA-23, aph(3') variants, and amrA, respectively. Regardless of the type of ARG, the MGEs linked with ARGs were also pathogen-specific. The sequence type of these pathogens was identified as high-risk international clones, with only a few lineages being predominant and region-specific. Whole-cell proteome analysis of extensively drug-resistant K. pneumoniae, A. baumannii, E. coli, and P. aeruginosa strains revealed differential abundances of resistance-associated proteins in the presence and absence of different classes of antibiotics. The pathogen-specific resistance signatures and differential abundance of AMR-associated proteins identified in this study should add value to AMR diagnostics and the choice of appropriate drug combinations for successful antimicrobial therapy.
Subject(s)
Anti-Bacterial Agents , Escherichia coli , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Escherichia coli/genetics , beta-Lactamases/genetics , beta-Lactamases/pharmacology , Proteomics , Drug Resistance, Bacterial , Drug Resistance, Multiple, Bacterial/genetics , Klebsiella pneumoniae , Microbial Sensitivity TestsABSTRACT
The contamination of lands and water by heavy toxic metal(loid)s is an environmental issue that needs serious attention as it poses a major threat to public health. The persistence of heavy metals/metalloids in the environment as well as their potentially dangerous effects on organisms underpins the need to restore the areas contaminated by heavy toxic metal(loid)s. Soil restoration can be achieved through a variety of different methods. Being more cost-effective and environmentally sustainable, phytoremediation has recently replaced traditional processes like soil washing and burning. Many plants have been intensively explored to eliminate various heavy metals from polluted soils through phytoextraction, which is a commonly used phytoremediation approach. The ability of chelants to enhance phytoextraction potential has also received wide attention owing to their ability to elevate the efficiency of plants in removing heavy metal(loid)s. Chelants have been found to improve plant growth and the activity of the defense system. Several chelants, either non-biodegradable or biodegradable, have been reported to augment the phytoextraction efficiencies of various plants. The problem of the leaching of heavy metal(loid)s and secondary pollution caused by non-biodegradable chelants can be overcome by the use of biodegradable chelants to an extent. This review is a brief report focusing on recent articles on chelate-assisted phytoextraction of heavy metal (loids) As, Cd, Cu, Cr, Hg, Ni, Pb, U, and Zn.
The review "Chelate assisted phytoextraction for effective rehabilitation of heavy metal(loid)s contaminated land" elaborates on the chelated assisted phytoextraction of eight metals and one metalloids along with their effective chelants.
Subject(s)
Mercury , Metals, Heavy , Soil Pollutants , Biodegradation, Environmental , Soil Pollutants/analysis , Metals, Heavy/analysis , Soil , PlantsABSTRACT
Infectious origins of a set of severe gastroduodenal diseases viz. gastritis, duodenal ulcer, gastric ulcer, gastric adenocarcinoma and gastric mucosa-associated lymphoid tissue (MALT) lymphoma were appreciated only after the discovery of H. pylori in 1983. In the past two decades, however, findings from many laboratories suggest that apart from H. pylori, several of the trillions of microbes that populate the human gastrointestinal tract and form microbiomes of the respective niches (like oral microbiome, esophageal microbiome, gastric microbiome and intestinal microbiome) may also participate in maintaining the healthy state of stomach and duodenum. Dysbiosis leading to alteration in the relative abundance of the key gastrointestinal microbes is associated with severe gastric diseases. For instance, an increased abundance of genera like Leptotrichia, Prevotella and Veillonella in gastric microbiome and a decreased abundance of Bifidobacterium in intestinal microbiome are associated with gastric cancer. H. pylori infection, apart from causing direct harm to the gastric epithelium by its virulence proteins like vacuolating cytotoxin A (VacA) and cytotoxin associated gene A (CagA), is also capable of triggering dysbiosis in stomach and intestinal microbiomes. In this chapter, we have discussed the possible roles of bacteria, viruses, fungi, archaea, protozoa and helminths in human gastrointestinal tracts in the context of H. pylori infection in stomach and various gastroduodenal diseases.
Subject(s)
Gastrointestinal Microbiome , Helicobacter Infections , Helicobacter pylori , Stomach Neoplasms , Humans , Helicobacter Infections/microbiology , Helicobacter Infections/pathology , Helicobacter pylori/genetics , Dysbiosis/complications , Antigens, Bacterial/genetics , Bacterial Proteins/genetics , Stomach , Stomach Neoplasms/microbiology , CytotoxinsABSTRACT
Physio-anatomical modifications and elemental distribution pattern in Acanthus ilicifolius subjected to Zn stress were analysed in this study. Survival of A. ilicifolius plants under a high concentration of ZnSO4 was compensated by the reduction in the photosynthetic efficacy. Micro and macro-elemental distribution pattern in the root tissues was significantly influenced by heavy metal exposure. Tolerance towards the excess toxic metal ions in the tissue of A. ilicifolius was aided by the modified anatomical features. Moreover, the increased deposition of Zn around the central vasculature of the root confirms the complexation of Zn2+ in the xylem vessels. Metal induced molecular level changes of root and leaf samples indicate the presence of OH, NH2, and CH3 deformation as well as C-O-H and C-O-C stretch. A prominent band corresponding to CH3 deformation, pointing hemicellulose fortification, occurs in the cell walls of the xylem, aiding in Zn localization. The phytostabilisation potential of A. ilicifolius is dependent on the coordinated responses which endow with phenotypic plasticity necessary to cope with Zn toxicity.
Subject(s)
Acanthaceae , Metals, Heavy , Plant Leaves , ZincABSTRACT
Since July 2007 prospective life-long follow-up (FU) for unrelated (URD) and related donors (RD) is mandatory in Switzerland and data on every allogeneic haematopoietic progenitor cell (HPC) donation are collected prospectively. We report the real-world experience of HPC donation during a 10-year study period (01.07.2007-30.06.2017) with basic characteristics and FU data. 1105 donors underwent 1155 HPC donation procedures. Eighty percent of first donations performed by 802 (73%) RDs and 303 (27%) URDs were peripheral blood stem cells (PBSC), 20% bone marrow (BM). Male donors were over-represented as URD (60% male vs 40% female). Main differences between RDs and URDs concerned age and pre-existing health disorders. RDs were significantly older at first donation (median age 48 years) compared to URD (34 years, p < 0.0001) and had more pre-existing health problems: 25% vs 9% in URD (p < 0.0001). No fatal complications occurred, collection related severe adverse events (SAE) after first donation were not significantly different between groups (RD 1.2%, URD 0.99%), incidence rates for neoplastic and autoimmune diseases did not exceed the rates of the general population. RDs are a more heterogeneous and potentially more vulnerable group, but if donor evaluation is performed appropriately, HPC donation is still safe.
Subject(s)
Tissue Donors , Unrelated Donors , Female , Follow-Up Studies , Hematopoietic Stem Cells , Humans , Male , Middle Aged , Prospective Studies , Switzerland/epidemiologyABSTRACT
The carcinogenic attribute of arsenic (As) has turned the world to focus more on the decontamination and declining the present level of As from the environment especially from the soil and water bodies. Phytoremediation has achieved a status of sustainable and eco-friendly approach of decontaminating pollutants, and in the present study, an attempt has been made to reveal the potential of As remediation by a halophyte plant, Acanthus ilicifolius L. Special attention has given to analyse the morphological, physiological and anatomical modulations in A. ilicifolius, developed in response to altering concentrations of Na2AsO4.7H2O (0, 70, 80 and 90 µM). Growth of A. ilicifolius under As treatments were diminished as assessed from the reduction in leaf area, root length, dry matter accumulation, and tissue water status. However, the plants exhibited a comparatively higher tolerance index (44%) even when grown in the higher concentrations of As (90 µM). Arsenic treatment induced reduction in the photochemical activities as revealed by the pigment content, chlorophyll stability index (CSI) and Chlorophyll a fluorescence parameter. Interestingly, the thickness and diameter of the xylem walls in the leaf as well as root tissues of As treated samples increased upon increasing the As concentration. The adaptive strategies exhibited by A. ilicifolius towards varying concentrations of As is the result of coordinated responses of morpho-physiological and anatomical attributes, which make the plant a promising candidate for As remediation, especially in wetlands.
Subject(s)
Acanthaceae , Arsenic , Soil Pollutants , Biodegradation, Environmental , Chlorophyll AABSTRACT
Microbes evolve rapidly by modifying their genome through mutations or acquisition of genetic elements. Antimicrobial resistance in Helicobacter pylori is increasingly prevalent in India. However, limited information is available about the genome of resistant H. pylori isolated from India. Our pan- and core-genome based analyses of 54 Indian H. pylori strains revealed plasticity of its genome. H. pylori is highly heterogenous both in terms of the genomic content and DNA sequence homology of ARGs and virulence factors. We observed that the H. pylori strains are clustered according to their geographical locations. The presence of point mutations in the ARGs and absence of acquired genetic elements linked with ARGs suggest target modifications are the primary mechanism of its antibiotic resistance. The findings of the present study would help in better understanding the emergence of drug-resistant H. pylori and controlling gastric disorders by advancing clinical guidance on selected treatment regimens.
Subject(s)
Helicobacter Infections , Helicobacter pylori , Anti-Bacterial Agents/pharmacology , Anti-Bacterial Agents/therapeutic use , Drug Resistance, Bacterial/genetics , Genomics , Helicobacter Infections/drug therapy , Helicobacter Infections/genetics , Helicobacter pylori/genetics , Humans , Virulence/geneticsABSTRACT
Background: The incidence of preterm birth (PTB) in India is around 13%. Specific bacterial communities or individual taxon living in the vaginal milieu of pregnant women is a potential risk factor for PTB and may play an important role in its pathophysiology. Besides, bacterial taxa associated with PTB vary across populations. Objective: Conduct a comparative analysis of vaginal microbiome composition and microbial genomic repertoires of women who enrolled in the Interdisciplinary Group for Advanced Research on Birth Outcomes - A DBT India Initiative (GARBH-Ini) pregnancy cohort to identify bacterial taxa associated with term birth (TB) and PTB in Indian women. Methods: Vaginal swabs were collected during all three trimesters from 38 pregnant Indian women who delivered spontaneous term (n=20) and preterm (n=18) neonates. Paired-end sequencing of V3-V4 region of 16S rRNA gene was performed using the metagenomic DNA isolated from vaginal swabs (n=115). Whole genome sequencing of bacterial species associated with birth outcomes was carried out by shotgun method. Lactobacillus species were grown anaerobically in the De Man, Rogosa and Sharpe (MRS) agar culture medium for isolation of genomic DNA and whole genome sequencing. Results: Vaginal microbiome of both term and preterm samples reveals similar alpha diversity indices. However, significantly higher abundance of Lactobacillus iners (p-value All_Trimesters<0.02), Megasphaera sp (p-value1st_Trimester <0.05), Gardnerella vaginalis (p-value2nd_Trimester= 0.01) and Sneathia sanguinegens (p-value2nd_Trimester <0.0001) were identified in preterm samples whereas higher abundance of L. gasseri (p-value3rd_Trimester =0.010) was observed in term samples by Wilcoxon rank-sum test. The relative abundance of L. iners, and Megasphaera sp. were found to be significantly different over time between term and preterm mothers. Analyses of the representative genomes of L. crispatus and L. gasseri indicate presence of secretory transcriptional regulator and several ribosomally synthesized antimicrobial peptides correlated with anti-inflammatory condition in the vagina. These findings indicate protective role of L. crispatus and L. gasseri in reducing the risk of PTB. Conclusion: Our findings indicate that the dominance of specific Lactobacillus species and few other facultative anaerobes are associated with birth outcomes.
Subject(s)
Premature Birth , Female , Fusobacteria , Humans , India , Infant, Newborn , Lactobacillus , Pregnancy , Premature Birth/epidemiology , RNA, Ribosomal, 16S/genetics , VaginaABSTRACT
Helicobacter pylori infection in stomach leads to gastric cancer, gastric ulcer, and duodenal ulcer. More than 1 million people die each year due to these diseases, but why most H. pylori-infected individuals remain asymptomatic while a certain proportion develops such severe gastric diseases remained an enigma. Several studies indicated that gastric and intestinal microbiota may play a critical role in the development of the H. pylori-associated diseases. However, no specific microbe in the gastric or intestinal microbiota has been clearly linked to H. pylori infection and related gastric diseases. Here, we studied H. pylori infection, its virulence genes, the intestinal microbiota, and the clinical status of Trivandrum residents (N = 375) in southwestern India by standard H. pylori culture, PCR genotype, Sanger sequencing, and microbiome analyses using Illumina Miseq and Nanopore GridION. Our analyses revealed that gastric colonization by virulent H. pylori strains (vacAs1i1m1cagA+) is necessary but not sufficient for developing these diseases. Conversely, distinct microbial pools exist in the lower gut of the H. pylori-infected vs. H. pylori-non-infected individuals. Bifidobacterium (belonging to the phylum Actinobacteria) and Bacteroides (belonging to the phylum Bacteroidetes) were present in lower relative abundance for the H. pylori+ group than the H. pylori- group (p < 0.05). On the contrary, for the H. pylori+ group, genus Dialister (bacteria belonging to the phylum Firmicutes) and genus Prevotella (bacteria belonging to the phylum Bacteroidetes) were present in higher abundance compared to the H. pylori- group (p < 0.05). Notably, those who carried H. pylori in the stomach and had developed aggressive gastric diseases also had extremely low relative abundance (p < 0.05) of several Bifidobacterium species (e.g., B. adolescentis, B. longum) in the lower gut suggesting a protective role of Bifidobacterium. Our results show the link between lower gastrointestinal microbes and upper gastrointestinal diseases. Moreover, the results are important for developing effective probiotic and early prognosis of severe gastric diseases.
ABSTRACT
OBJECTIVES: As of December, 1st, 2020, coronavirus disease 2019 (COVID-19) caused by SARS-CoV-2, resulted in more than 1 472 917 deaths worldwide and death toll is still increasing exponentially. Many COVID-19 infected people are asymptomatic or experience moderate symptoms and recover without medical intervention. However, older people and those with comorbid hypertension, diabetes, obesity, or heart disease are at higher risk of mortality. Because current therapeutic options for COVID-19 patients are limited specifically for this elderly population at risk, Biophytis is developing BIO101 (20-hydroxyecdysone, a Mas receptor activator) as a new treatment option for managing patients with SARS-CoV-2 infection at the severe stage. The angiotensin converting enzyme 2 (ACE2) serves as a receptor for SARS-CoV-2. Interaction between ACE2 and SARS-CoV2 spike protein seems to alter the function of ACE2, a key player in the renin-angiotensin system (RAS). The clinical picture of COVID-19 includes acute respiratory distress syndrome (ARDS), cardiomyopathy, multiorgan dysfunction and shock, all of which might result from an imbalance of the RAS. We propose that RAS balance could be restored in COVID-19 patients through MasR activation downstream of ACE2 activity, with 20-hydroxyecdysone (BIO101) a non-peptidic Mas receptor (MasR) activator. Indeed, MasR activation by 20-hydroxyecdysone harbours anti-inflammatory, anti-thrombotic, and anti-fibrotic properties. BIO101, a 97% pharmaceutical grade 20-hydroxyecdysone could then offer a new therapeutic option by improving the respiratory function and ultimately promoting survival in COVID-19 patients that develop severe forms of this devastating disease. Therefore, the objective of this COVA study is to evaluate the safety and efficacy of BIO101, whose active principle is 20-hydroxyecdysone, in COVID-19 patients with severe pneumonia. TRIAL DESIGN: Randomized, double-blind, placebo-controlled, multi-centre, group sequential and adaptive which will be conducted in 2 parts. Part 1: Ascertain the safety and tolerability of BIO101 and obtain preliminary indication of the activity of BIO101, in preventing respiratory deterioration in the target population Part 2: Re-assessment of the sample size needed for the confirmatory part 2 and confirmation of the effect of BIO101 observed in part 1 in the target population. The study is designed as group sequential to allow an efficient run-through, from obtaining an early indication of activity to a final confirmation. And adaptive - to allow accumulation of early data and adapt sample size in part 2 in order to inform the final design of the confirmatory part of the trial. PARTICIPANTS: Inclusion criteria 1. Age: 45 and above 2. A confirmed diagnosis of COVID-19 infection, within the last 14 days, prior to randomization, as determined by PCR or other approved commercial or public health assay, in a specimen as specified by the test used. 3. Hospitalized, in observation or planned to be hospitalized due to COVID-19 infection symptoms with anticipated hospitalization duration ≥3 days 4. With evidence of pneumonia based on all of the following: a. Clinical findings on a physical examination b. Respiratory symptoms developed within the past 7 days 5. With evidence of respiratory decompensation that started not more than 4 days before start of study medication and present at screening, meeting one of the following criteria, as assessed by healthcare staff: a. Tachypnea: ≥25 breaths per minute b. Arterial oxygen saturation ≤92% c. A special note should be made if there is suspicion of COVID-19-related myocarditis or pericarditis, as the presence of these is a stratification criterion 6. Without a significant deterioration in liver function tests: a. ALT and AST ≤ 5x upper limit of normal (ULN) b. Gamma-glutamyl transferase (GGT) ≤ 5x ULN c. Total bilirubin ≤ 5×ULN 7. Willing to participate and able to sign an informed consent form (ICF). Or, when relevant, a legally authorized representative (LAR) might sign the ICF on behalf of the study participant 8. Female participants should be: at least 5 years post-menopausal (i.e., persistent amenorrhea 5 years in the absence of an alternative medical cause) or surgically sterile; OR a. Have a negative urine pregnancy test at screening b. Be willing to use a contraceptive method as outlined in inclusion criterion 9 from screening to 30 days after last dose. 9. Male participants who are sexually active with a female partner must agree to the use of an effective method of birth control throughout the study and until 3 months after the last administration of the investigational product. (Note: medically acceptable methods of contraception that may be used by the participant and/or partner include combined oral contraceptive, contraceptive vaginal ring, contraceptive injection, intrauterine device, etonogestrel implant, each supplemented with a condom, as well as sterilization and vasectomy). 10. Female participants who are lactating must agree not to breastfeed during the study and up to 14 days after the intervention. 11. Male participants must agree not to donate sperm for the purpose of reproduction throughout the study and until 3 months after the last administration of the investigational product. 12. For France only: Being affiliated with a European Social Security. Exclusion criteria 1. Not needing or not willing to remain in a healthcare facility during the study 2. Moribund condition (death likely in days) or not expected to survive for >7 days - due to other and non-COVID-19 related conditions 3. Participant on invasive mechanical ventilation via an endotracheal tube, or extracorporeal membrane oxygenation (ECMO), or high-flow Oxygen (delivery of oxygen at a flow of ≥16 L/min.). 4. Participant is not able to take medications by mouth (as capsules or as a powder, mixed in water). 5. Disallowed concomitant medication: Consumption of any herbal products containing 20-hydroxyecdysone and derived from Leuzea carthamoides; Cyanotis vaga or Cyanotis arachnoidea is not allowed (e.g. performance enhancing agents). 6. Any known hypersensitivity to any of the ingredients, or excipients of the study medication, BIO101. 7. Renal disease requiring dialysis, or known renal insufficiency (eGFR≤30 mL/min/1.73 m2, based on Cockcroft & Gault formula). 8. In France only: a. Non-affiliation to compulsory French social security scheme (beneficiary or right-holder). b. Being under tutelage or legal guardianship. Participants will be recruited from approximately 30 clinical centres in Belgium, France, the UK, USA and Brazil. Maximum patients' participation in the study will last 28 days. Follow-up of participants discharged from hospital will be performed through post-intervention phone calls at 14 (± 2) and 60 (± 4) days. INTERVENTION AND COMPARATOR: Two treatment arms will be tested in this study: interventional arm 350 mg b.i.d. of BIO101 (AP 20-hydroxyecdysone) and placebo comparator arm 350 mg b.i.d of placebo. Administration of daily dose is the same throughout the whole treatment period. Participants will receive the study medication while hospitalized for up to 28 days or until a clinical endpoint is reached (i.e., 'negative' or 'positive' event). Participants who are officially discharged from hospital care will no longer receive study medication. MAIN OUTCOMES: Primary study endpoint: The proportion of participants with 'negative' events up to 28 days. 'Negative' events are defined as respiratory deterioration and all-cause mortality. For the purpose of this study, respiratory deterioration will be defined as any of the following: Requiring mechanical ventilation (including cases that will not be intubated due to resource restrictions and triage). Requiring extracorporeal membrane oxygenation (ECMO). Requiring high-flow oxygen defined as delivery of oxygen at a flow of ≥16 L/min. Only if the primary endpoint is significant at the primary final analysis the following Key secondary endpoints will be tested in that order: Proportion of participants with events of respiratory failure at Day 28 Proportion of participants with 'positive' events at Day 28. Proportion of participants with events of all-cause mortality at Day 28 A 'positive' event is defined as the official discharge from hospital care by the department due to improvement in participant condition. Secondary and exploratory endpoints: In addition, a variety of functional measures and biomarkers (including the SpO2 / FiO2 ratio, viral load and markers related to inflammation, muscles, tissue and the RAS / MAS pathways) will also be collected. RANDOMIZATION: Randomization is performed using an IBM clinical development IWRS system during the baseline visit. Block-permuted randomization will be used to assign eligible participants in a 1:1 ratio. In part 1, randomization will be stratified by RAS pathway modulator use (yes/no) and co-morbidities (none vs. 1 and above). In Part 2, randomization will be stratified by centre, gender, RAS pathway modulator use (yes/no), co-morbidities (none vs. 1 and above), receiving Continuous Positive Airway Pressure/Bi-level Positive Airway Pressure (CPAP/BiPAP) at study entry (Yes/No) and suspicion of COVID-19 related myocarditis or pericarditis (present or not). BLINDING (MASKING): Participants, caregivers, and the study team assessing the outcomes are blinded to group assignment. All therapeutic units (TU), BIO101 b.i.d. or placebo b.i.d., cannot be distinguished in compliance with the double-blind process. An independent data-monitoring committee (DMC) will conduct 2 interim analyses. A first one based on the data from part 1 and a second from the data from parts 1 and 2. The first will inform about BIO101 safety, to allow the start of recruitment into part 2 followed by an analysis of the efficacydata, to obtain an indication of activity. The second interim analysis will inform about the sample size that will be required for part 2, in order to achieve adequate statistical power. Numbers to be randomised (sample size) Number of participants randomized: up to 465, in total Part 1: 50 (to obtain the proof of concept in COVID-19 patients). Part 2: 310, potentially increased by 50% (up to 465, based on interim analysis 2) (to confirm the effects of BIO101 observed in part 1). TRIAL STATUS: The current protocol Version is V 10.0, dated on 24.09.2020. The recruitment that started on September 1st 2020 is ongoing and is anticipated to finish for the whole study by March2021. TRIAL REGISTRATION: The trial was registered before trial start in trial registries: EudraCT , No. 2020-001498-63, registered May 18, 2020; and Clinicaltrials.gov, identifier NCT04472728 , registered July 15, 2020. FULL PROTOCOL: The full protocol is attached as an additional file, accessible from the Trials website (Additional file 1). In the interest in expediting dissemination of this material, the familiar formatting has been eliminated; this Letter serves as a summary of the key elements of the full protocol.
Subject(s)
COVID-19 Drug Treatment , Ecdysterone/therapeutic use , Respiratory Insufficiency/drug therapy , Aged , Aged, 80 and over , Angiotensin-Converting Enzyme 2/metabolism , COVID-19/physiopathology , Disease Progression , Double-Blind Method , Extracorporeal Membrane Oxygenation/statistics & numerical data , Hospitalization , Humans , Hypoxia/physiopathology , Middle Aged , Mortality , Oxygen Inhalation Therapy/statistics & numerical data , Proto-Oncogene Mas , Proto-Oncogene Proteins/metabolism , Randomized Controlled Trials as Topic , Receptors, Coronavirus/metabolism , Receptors, G-Protein-Coupled/metabolism , Renin-Angiotensin System , Respiration, Artificial/statistics & numerical data , Respiratory Insufficiency/physiopathology , SARS-CoV-2 , Spike Glycoprotein, Coronavirus/metabolism , Tachypnea/physiopathology , Treatment OutcomeABSTRACT
The Canadian Cardiovascular Society (CCS) atrial fibrillation (AF) guidelines program was developed to aid clinicians in the management of these complex patients, as well as to provide direction to policy makers and health care systems regarding related issues. The most recent comprehensive CCS AF guidelines update was published in 2010. Since then, periodic updates were published dealing with rapidly changing areas. However, since 2010 a large number of developments had accumulated in a wide range of areas, motivating the committee to complete a thorough guideline review. The 2020 iteration of the CCS AF guidelines represents a comprehensive renewal that integrates, updates, and replaces the past decade of guidelines, recommendations, and practical tips. It is intended to be used by practicing clinicians across all disciplines who care for patients with AF. The Grading of Recommendations, Assessment, Development and Evaluations (GRADE) system was used to evaluate recommendation strength and the quality of evidence. Areas of focus include: AF classification and definitions, epidemiology, pathophysiology, clinical evaluation, screening and opportunistic AF detection, detection and management of modifiable risk factors, integrated approach to AF management, stroke prevention, arrhythmia management, sex differences, and AF in special populations. Extensive use is made of tables and figures to synthesize important material and present key concepts. This document should be an important aid for knowledge translation and a tool to help improve clinical management of this important and challenging arrhythmia.
Le programme de lignes directrices de la Société canadienne de cardiologie (SCC) en matière de fibrillation auriculaire (FA) a été élaboré pour aider les cliniciens à prendre en charge ces patients complexes, ainsi que pour orienter les décideurs politiques et les systèmes de soins de santé sur des questions connexes. La dernière édition complète des lignes directrices de la SCC en matière de FA a été publiée en 2010. Depuis lors, des mises à jour périodiques ont été publiées, traitant de domaines en évolution rapide. Cependant, en 2020, un grand nombre de développements s'y étaient ajoutés, couvrant un large éventail de domaines, ce qui a motivé le comité à créer une refonte complète des lignes directrices. L'édition 2020 des lignes directrices de la SCC en matière de FA représente un renouvellement complet qui intègre, met à jour et remplace les lignes directrices, les recommandations et les conseils pratiques des dix dernières années. Elle est destinée à être utilisée par les cliniciens praticiens de toutes les disciplines qui s'occupent de patients souffrant de FA. L'approche GRADE (Gradation des Recommandations, de l'Appréciation, du Développement et des Évaluations) a été utilisée pour évaluer la pertinence des recommandations et la qualité des résultats. Les domaines d'intérêt incluent : la classification et les définitions de la FA, son épidémiologie, sa physiopathologie, l'évaluation clinique, le dépistage de la FA, la détection et la gestion des facteurs de risque modifiables, l'approche intégrée de la gestion de la FA, la prévention des accidents vasculaires cérébraux, la gestion de l'arythmie, les différences entre les sexes et la FA dans des populations particulières. Des tableaux et figures ont été largement utilisés pour synthétiser les éléments importants et présenter les concepts clés. Ce document devrait représenter une aide importante pour l'intégration des connaissances et un outil pour aider à améliorer la gestion clinique de cette arythmie importante et difficile à traiter.
Subject(s)
Humans , Male , Female , Atrial Fibrillation/diagnosis , Atrial Fibrillation/therapy , Atrial Fibrillation/classification , Atrial Fibrillation/physiopathology , Atrial Fibrillation/epidemiology , Risk Groups , Algorithms , Sex Factors , Risk Factors , Critical Pathways , Stroke/prevention & controlABSTRACT
The human pathogen Vibrio cholerae is the causative agent of severe diarrheal disease known as cholera. Of the more than 200 "O" serogroups of this pathogen, O1 and O139 cause cholera outbreaks and epidemics. The rest of the serogroups, collectively known as non-O1/non-O139 cause sporadic moderate or mild diarrhea and also systemic infections. Pathogenic V. cholerae circulates between nutrient-rich human gut and nutrient-deprived aquatic environment. As an autochthonous bacterium in the environment and as a human pathogen, V. cholerae maintains its survival and proliferation in these two niches. Growth in the gastrointestinal tract involves expression of several genes that provide bacterial resistance against host factors. An intricate regulatory program involving extracellular signaling inputs is also controlling this function. On the other hand, the ability to store carbon as glycogen facilitates bacterial fitness in the aquatic environment. To initiate the infection, V. cholerae must colonize the small intestine after successfully passing through the acid barrier in the stomach and survive in the presence of bile and antimicrobial peptides in the intestinal lumen and mucus, respectively. In V. cholerae, virulence is a multilocus phenomenon with a large functionally associated network. More than 200 proteins have been identified that are functionally linked to the virulence-associated genes of the pathogen. Several of these genes have a role to play in virulence and/or in functions that have importance in the human host or the environment. A total of 524 genes are differentially expressed in classical and El Tor strains, the two biotypes of V. cholerae serogroup O1. Within the host, many immune and biological factors are able to induce genes that are responsible for survival, colonization, and virulence. The innate host immune response to V. cholerae infection includes activation of several immune protein complexes, receptor-mediated signaling pathways, and other bactericidal proteins. This article presents an overview of regulation of important virulence factors in V. cholerae and host response in the context of pathogenesis.
Subject(s)
Cholera , Vibrio cholerae , Disease Outbreaks , Humans , Vibrio cholerae/genetics , Virulence , Virulence Factors/geneticsABSTRACT
Bacterial species are hosts to horizontally acquired mobile genetic elements (MGEs), which encode virulence, toxin, antimicrobial resistance, and other metabolic functions. The bipartite genome of Vibrio cholerae harbors sporadic and conserved MGEs that contribute in the disease development and survival of the pathogens. For a comprehensive understanding of dynamics of MGEs in the bacterial genome, we engineered the genome of V. cholerae and examined in vitro and in vivo stability of genomic islands (GIs), integrative conjugative elements (ICEs), and prophages. Recombinant vectors carrying the integration module of these GIs, ICE and CTXΦ, helped us to understand the efficiency of integrations of MGEs in the V. cholerae chromosome. We have deleted more than 250 acquired genes from 6 different loci in the V. cholerae chromosome and showed contribution of CTX prophage in the essentiality of SOS response master regulator LexA, which is otherwise not essential for viability in other bacteria, including Escherichia coli In addition, we observed that the core genome-encoded RecA helps CTXΦ to bypass V. cholerae immunity and allow it to replicate in the host bacterium in the presence of similar prophage in the chromosome. Finally, our proteomics analysis reveals the importance of MGEs in modulating the levels of cellular proteome. This study engineered the genome of V. cholerae to remove all of the GIs, ICEs, and prophages and revealed important interactions between core and acquired genomes.
Subject(s)
Genome, Bacterial/genetics , Genomic Islands/genetics , Vibrio cholerae/genetics , Bacterial Proteins/genetics , Conjugation, Genetic/genetics , Genetic Engineering , Interspersed Repetitive Sequences/genetics , Prophages/genetics , Serine Endopeptidases/genetics , Vibrio cholerae/pathogenicityABSTRACT
In multisite neuroimaging studies there is often unwanted technical variation across scanners and sites. These "scanner effects" can hinder detection of biological features of interest, produce inconsistent results, and lead to spurious associations. We propose mica (multisite image harmonization by cumulative distribution function alignment), a tool to harmonize images taken on different scanners by identifying and removing within-subject scanner effects. Our goals in the present study were to (1) establish a method that removes scanner effects by leveraging multiple scans collected on the same subject, and, building on this, (2) develop a technique to quantify scanner effects in large multisite studies so these can be reduced as a preprocessing step. We illustrate scanner effects in a brain MRI study in which the same subject was measured twice on seven scanners, and assess our method's performance in a second study in which ten subjects were scanned on two machines. We found that unharmonized images were highly variable across site and scanner type, and our method effectively removed this variability by aligning intensity distributions. We further studied the ability to predict image harmonization results for a scan taken on an existing subject at a new site using cross-validation.
Subject(s)
Brain Mapping/methods , Brain/anatomy & histology , Brain/diagnostic imaging , Image Processing, Computer-Assisted/methods , Magnetic Resonance Imaging , Algorithms , Artifacts , Humans , Male , Middle Aged , Reproducibility of ResultsABSTRACT
BACKGROUND AND PURPOSE: Cellular uptake of the manganese ion, when administered as a contrast agent for MR imaging, can noninvasively highlight cellular activity and disease processes in both animals and humans. The purpose of this study was to explore the enhancement profile of manganese in patients with multiple sclerosis. MATERIALS AND METHODS: Mangafodipir is a manganese chelate that was clinically approved for MR imaging of liver lesions. We present a case series of 6 adults with multiple sclerosis who were scanned at baseline with gadolinium, then injected with mangafodipir, and followed at variable time points thereafter. RESULTS: Fourteen new lesions formed during or shortly before the study, of which 10 demonstrated manganese enhancement of varying intensity, timing, and spatial pattern. One gadolinium-enhancing extra-axial mass, presumably a meningioma, also demonstrated enhancement with manganese. Most interesting, manganese enhancement was detected in lesions that formed in the days after mangafodipir injection, and this enhancement persisted for several weeks, consistent with contrast coming from intracellular uptake of manganese. Some lesions demonstrated a diffuse pattern of manganese enhancement in an area larger than that of both gadolinium enhancement and T2-FLAIR signal abnormality. CONCLUSIONS: This work demonstrates the first use of a manganese-based contrast agent to enhance MS lesions on MR imaging. Multiple sclerosis lesions were enhanced with a temporal and spatial profile distinct from that of gadolinium. Further experiments are necessary to uncover the mechanism of manganese contrast enhancement as well as cell-specific uptake.